Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA issues long-awaited guidance on biosimilar naming
FDA issues long-awaited guidance on biosimilar naming
FDA issues long-awaited guidance on biosimilar naming
Submitted by
admin
on January 13, 2017 - 9:37am
Source:
BioPharma Dive
News Tags:
FDA
biosimilars
drug names
Headline:
FDA issues long-awaited guidance on biosimilar naming
Do Not Allow Advertisers to Use My Personal information
